Appili to begin a phase 2 study of an approved antiviralLast month, Canadian regulators provided clearance for Appili Therapeutics to begin a phase 2 study of an approved antiviral therapy as a potential preventative treatment against COVID-19 outbreaks.
The study will enroll 760 participants who are in long-term care facilities in Ontario. Though others are looking at the drug as a possible treatment for COVID-19, this is the first study to consider its potential to prevent outbreaks.
We spoke to Armand Balboni, CEO of Appili, about drug, how it works, and its potential to prevent outbreaks of COVID-19 in high-risk populations.
https://soundcloud.com/levine-media-group/testing-if-an-approved-antiviral-may-prevent-covid-19-outbreaks